OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Total Non-Current Liabilities

Last Annual Value

12.00K

3-Year CAGR

-94%

5-Year CAGR

-83%

10-Year CAGR

-59%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Total Non-Current Liabilities

OKUR · NASDAQ
CompanyTotal Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
12.00K
-95.5%-54.4%N/A 
11.76M
-15.7%119.4%-2.4%
0.00
N/AN/AN/A
14.80M
-25.3%4.9%N/A
9.51M
-6.8%-9.2%1.1%
63.14M
97.9%22.0%N/A
35.99M
-0.5%554.4%N/A
91.71M
-9.9%20.0%-3.6%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47